Cargando…

Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review

PURPOSE: The impact of sarcopenia on the future liver remnant (FLR) growth after portal vein occlusion, including portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has gained increasing interest. This systematic review aimed to exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiang, Wang, Anrong, Li, Zhen, Sparrelid, Ernesto, Brismar, Torkel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730229/
https://www.ncbi.nlm.nih.gov/pubmed/36505848
http://dx.doi.org/10.3389/fonc.2022.1064785
_version_ 1784845618876776448
author Wang, Qiang
Wang, Anrong
Li, Zhen
Sparrelid, Ernesto
Brismar, Torkel B.
author_facet Wang, Qiang
Wang, Anrong
Li, Zhen
Sparrelid, Ernesto
Brismar, Torkel B.
author_sort Wang, Qiang
collection PubMed
description PURPOSE: The impact of sarcopenia on the future liver remnant (FLR) growth after portal vein occlusion, including portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has gained increasing interest. This systematic review aimed to explore whether sarcopenia was associated with insufficient FLR growth after PVE/ALPPS stage-1. METHODS: A systematic literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library up to 05 July 2022. Studies evaluating the influence of sarcopenia on FLR growth after PVE/ALPPS stage-1 in patients with liver cancer were included. A predefined table was used to extract information including the study and patient characteristics, sarcopenia measurement, FLR growth, post-treatment complications and post-hepatectomy liver failure, resection rate. Research quality was evaluated by the Newcastle-Ottawa Scale. RESULTS: Five studies consisting of 609 patients were included in this study, with a sample size ranging from 42 to 306 (median: 90) patients. Only one study was multicenter research. The incidence of sarcopenia differed from 40% to 67% (median: 63%). Skeletal muscle index based on pretreatment computed tomography was the commonly used parameter for sarcopenia evaluation. All included studies showed that sarcopenia impaired the FLR growth after PVE/ALPPS stage-1. However, the association between sarcopenia and post-treatment complications, post-hepatectomy liver failure, and resection rate remains unclear. All studies showed moderate-to-high quality. CONCLUSIONS: Sarcopenia seems to be prevalent in patients undergoing PVE/ALPPS and may be a risk factor for impaired liver growth after PVE/ALPPS stage-1 according to currently limited evidence. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/, identifier INPLASY202280038.
format Online
Article
Text
id pubmed-9730229
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97302292022-12-09 Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review Wang, Qiang Wang, Anrong Li, Zhen Sparrelid, Ernesto Brismar, Torkel B. Front Oncol Oncology PURPOSE: The impact of sarcopenia on the future liver remnant (FLR) growth after portal vein occlusion, including portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has gained increasing interest. This systematic review aimed to explore whether sarcopenia was associated with insufficient FLR growth after PVE/ALPPS stage-1. METHODS: A systematic literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library up to 05 July 2022. Studies evaluating the influence of sarcopenia on FLR growth after PVE/ALPPS stage-1 in patients with liver cancer were included. A predefined table was used to extract information including the study and patient characteristics, sarcopenia measurement, FLR growth, post-treatment complications and post-hepatectomy liver failure, resection rate. Research quality was evaluated by the Newcastle-Ottawa Scale. RESULTS: Five studies consisting of 609 patients were included in this study, with a sample size ranging from 42 to 306 (median: 90) patients. Only one study was multicenter research. The incidence of sarcopenia differed from 40% to 67% (median: 63%). Skeletal muscle index based on pretreatment computed tomography was the commonly used parameter for sarcopenia evaluation. All included studies showed that sarcopenia impaired the FLR growth after PVE/ALPPS stage-1. However, the association between sarcopenia and post-treatment complications, post-hepatectomy liver failure, and resection rate remains unclear. All studies showed moderate-to-high quality. CONCLUSIONS: Sarcopenia seems to be prevalent in patients undergoing PVE/ALPPS and may be a risk factor for impaired liver growth after PVE/ALPPS stage-1 according to currently limited evidence. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/, identifier INPLASY202280038. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9730229/ /pubmed/36505848 http://dx.doi.org/10.3389/fonc.2022.1064785 Text en Copyright © 2022 Wang, Wang, Li, Sparrelid and Brismar https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Qiang
Wang, Anrong
Li, Zhen
Sparrelid, Ernesto
Brismar, Torkel B.
Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review
title Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review
title_full Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review
title_fullStr Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review
title_full_unstemmed Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review
title_short Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review
title_sort impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: a systematic review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730229/
https://www.ncbi.nlm.nih.gov/pubmed/36505848
http://dx.doi.org/10.3389/fonc.2022.1064785
work_keys_str_mv AT wangqiang impactofsarcopeniaonthefutureliverremnantgrowthafterportalveinembolizationandassociatingliverpartitionandportalveinligationforstagedhepatectomyinpatientswithlivercancerasystematicreview
AT wanganrong impactofsarcopeniaonthefutureliverremnantgrowthafterportalveinembolizationandassociatingliverpartitionandportalveinligationforstagedhepatectomyinpatientswithlivercancerasystematicreview
AT lizhen impactofsarcopeniaonthefutureliverremnantgrowthafterportalveinembolizationandassociatingliverpartitionandportalveinligationforstagedhepatectomyinpatientswithlivercancerasystematicreview
AT sparrelidernesto impactofsarcopeniaonthefutureliverremnantgrowthafterportalveinembolizationandassociatingliverpartitionandportalveinligationforstagedhepatectomyinpatientswithlivercancerasystematicreview
AT brismartorkelb impactofsarcopeniaonthefutureliverremnantgrowthafterportalveinembolizationandassociatingliverpartitionandportalveinligationforstagedhepatectomyinpatientswithlivercancerasystematicreview